Exchange: NASDAQ·Updated 05:12 PM EDT
RXRX logo

RXRXRecursion Pharmaceuticals Inc

$3.80
$0.13
(3.54%)
Today
Closed $3.80
$0.00
(0.00%)
After Hours
EarningsAug 5
Mkt Cap$1.95B
Vol32.57M
News
all
press releases
As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data
As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data PR Newswire NEW YORK, July 1, 2026 Issued on behalf...
PR Newswire
News Placeholder
More News
News Placeholder
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire NEW YORK, June 30, 2026 Issued on behalf of GT Biopharma, Inc.GT...
PR Newswire
News Placeholder
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsRecursion Pharmaceuticals leverages an artificial intelligence platform to decode biology and automate the drug discovery process...
Nasdaq News: Markets
News Placeholder
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.
Zacks
News Placeholder
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.
Zacks
News Placeholder
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It PR Newswire NEW YORK, June 16, 2026 Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful...
PR Newswire
News Placeholder
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving 5.12% from the previous trading session.
Zacks
News Placeholder
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Recursion Pharmaceuticals vs. Schrodinger: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsRecursion Pharmaceuticals uses its AI-driven platform to manage a deep pipeline of drug candidates through strategic partnerships with industry giants...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.